by Admin | May 8, 2025
Supporting Innovation from Research to Clinical Manufacturing In the rapidly evolving field of RNA therapeutics, precise and efficient delivery remains a critical challenge—especially for systemic administration. At Areterna, we are helping solve this challenge by...
by Admin | Mar 24, 2025
As we step into 2025, we have entered the next era of RNA therapeutics. The global biotech and pharmaceutical industries are increasingly integrating mRNA-based medicines and the undeniable potential of RNA into their discovery and development pipelines. While the...
by Admin | Feb 1, 2025
Stay ahead in mRNA research and development with our newly available capped and uncapped reference standards! A linear mRNA molecule primarily consists of five components: the 5′ cap structure (5′ Cap), the 5′ untranslated region (5′ UTR), the...
by Admin | Nov 7, 2024
Introduction Modified nucleoside triphosphates (NTPs) are the master keys that unlock the therapeutic potential of mRNA. By strategically incorporating these chemically modified building blocks during mRNA synthesis, researchers can enhance stability, translation...
by Admin | Oct 22, 2024
Introduction The development of mRNA vaccines to fight COVID-19 marked a transformative leap in medicine, showcasing the power of RNA technology to tackle infectious diseases. Despite its groundbreaking success, mRNA has some limitations—such as instability, the need...
by Admin | Oct 14, 2024
mRNA therapeutics have emerged as a revolutionary force in medicine, riding the wave of success initially generated by mRNA vaccines for COVID-19. However, as the field progresses from vaccines to protein replacement therapies and beyond, it faces distinct hurdles,...
